Celon Pharma S.A. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported revenue was PLN 216.57 million compared to PLN 194.59 million a year ago. Net loss was PLN 28.12 million compared to PLN 39.28 million a year ago.

Basic loss per share from continuing operations was PLN 0.55 compared to PLN 0.77 a year ago. Diluted loss per share from continuing operations was PLN 0.55 compared to PLN 0.77 a year ago.